Beam Therapeutics
BEAM
209 hedge funds and large institutions have $3.43B invested in Beam Therapeutics in 2021 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 66 increasing their positions, 43 reducing their positions, and 14 closing their positions.
364% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 14
100% more funds holding in top 10
Funds holding in top 10: 5 → 10 (+5)
53% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 43
49% more call options, than puts
Call options by funds: $79.5M | Put options by funds: $53.2M
32% more funds holding
Funds holding: 158 → 209 (+51)
14% more capital invested
Capital invested by funds: $3.01B → $3.43B (+$422M)
5.22% more ownership
Funds ownership: 63.69% → 68.91% (+5.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$347M |
| 2 |
MM
MWG Management
Road Town, Tortola,
British Virgin Islands
|
+$225M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$56.4M |
| 4 |
PA
Perceptive Advisors
New York
|
+$51.1M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$49.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$119M |
| 2 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$85M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$71.6M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$66.4M |
| 5 |
Alkeon Capital Management
New York
|
-$40.8M |
BEAM Hedge Fund Activity: Q1 2021 in Review
209 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q1 2021, worth a combined $3.43B — up 14% from $3.01B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new BEAM positions and 14 closed out — a net gain of 51 holders — while 66 added to existing stakes and 43 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $347M. The largest seller was Redmile Group, cutting an estimated $119M.
- 209 institutional investors held Beam Therapeutics (BEAM) as of Q1 2021, up from 158 in Q4 2020.
- Funds reported $3.43B of Beam Therapeutics stock for Q1 2021, up 14% quarter-over-quarter.
- 65 funds opened new Beam Therapeutics positions in Q1 2021 and 14 closed out, a net change of +51 holders.
- The largest Beam Therapeutics buyer in Q1 2021 was ARK Investment Management, an estimated $347M added.
- The largest Beam Therapeutics seller in Q1 2021 was Redmile Group, an estimated $119M sold.
Based on aggregated 13F filings for Q1 2021.